Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vanessa Velotta"'
Autor:
Massimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, Elisabetta Abruzzese, Gianni Binotto, Luigi Scaffidi, Maddalena Cordioli, Daniela Damiani, Eros Di Bona, Malgorzata Monika Trawinska, Ilaria Tanasi, Maria Vittoria Dubbini, Vanessa Velotta, Giulia Ceccarelli, Elisabetta Pierdomenico, Mariella Lo Schirico, Gianpietro Semenzato, Marco Ruggeri, Renato Fanin, Evelina Tacconelli, Giovanni Pizzolo, Mauro Krampera
Publikováno v:
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Abstract Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclin
Externí odkaz:
https://doaj.org/article/4e846c090a3840e789287e4d5b68960c
Autor:
Maria Vittoria Dubbini, Mariella Lo Schirico, Gianpietro Semenzato, Massimiliano Bonifacio, Mario Tiribelli, Luigi Scaffidi, Maddalena Cordioli, Giulia Ceccarelli, Eros Di Bona, Renato Fanin, Vanessa Velotta, Maria Cristina Miggiano, Gianni Binotto, Malgorzata Monika Trawinska, Evelina Tacconelli, Mauro Krampera, Daniela Damiani, Ilaria Tanasi, Elisabetta Abruzzese, Giovanni Pizzolo, Marco Ruggeri, Elisabetta Pierdomenico
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Cancer Medicine, Vol 10, Iss 18, Pp 6310-6316 (2021)
Background Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf0a18c9ca6e471c6888783d5029b26b
http://europepmc.org/articles/PMC8446554
http://europepmc.org/articles/PMC8446554
Autor:
Mario Tiribelli, Massimiliano Bonifacio, Eros Di Bona, Giovanni Pizzolo, Evelina Tacconelli, Renato Fanin, Malgorzata Monika Trawinska, Mauro Krampera, Giulia Ceccarelli, Daniela Damiani, Maria Vittoria Dubbini, Luigi Scaffidi, Marco Ruggeri, Elisabetta Pierdomenico, Maddalena Cordioli, Vanessa Velotta, Maria Cristina Miggiano, Gianpietro Semenzato, Gianni Binotto, Mariella Loschirico
Publikováno v:
Blood
Background. Clinical course of the novel Coronavirus (SARS-CoV-2) Disease 2019 (COVID-19) is extremely heterogeneous, and infected individuals may be asymptomatic or develop acute respiratory manifestations. Elderly people and patients with pre-exist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce6d6addfb5851e9a3878254f9dbae8
https://doi.org/10.1182/blood-2020-140032
https://doi.org/10.1182/blood-2020-140032
Autor:
Michele Cavo, Vanessa Velotta, Fabrizio Pane, Caterina De Benedittis, Michele Baccarani, Gianantonio Rosti, Sara Galimberti, Fausto Castagnetti, Monica Crugnola, Antonella Russo Rossi, Luigiana Luciano, Massimiliano Bonifacio, Alessandra Iurlo, Adam S Corner, Dianna Maar, Stefano Pileri, Maria Antonella Laginestra, Francesca Lunghi, Luana Bavaro, Simona Soverini, Margherita Martelli, Antonio Percesepe, Mario Tiribelli, Giovanni Martinelli, Mariella D'Adda, Gabriele Gugliotta, Fabio Stagno, Patrizia Pregno, Giuseppe Saglio, Claudia Baratè
Publikováno v:
Blood. 134:661-661
A variety of mechanisms underlie the lack or loss of response to TKIs in patients (pts) with CML, but acquisition of point mutations in the BCR-ABL1 KD is, at present, the only actionable one. Detection of a TKI-resistant mutation by Sanger Sequencin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd59d2f6a4a9a40561f0c14fb5be105e
https://doi.org/10.1182/blood-2019-126767
https://doi.org/10.1182/blood-2019-126767
Autor:
Agostina Siniscalchi, Patrizia Caraffa, Tommaso Caravita, Vanessa Velotta, Silvia Gentili, Paolo de Fabritiis, Massimo Offidani, Pietro Leoni
Publikováno v:
Blood. 118:5135-5135
Abstract 5135 IMiDs exert various effects on the immune system altering cytokine production, regulating T cell costimulation and enhancing NK cell cytotoxicity. Particularly, lenalidomide is 50000 times more potent than thalidomide in inhibiting tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a925dea11c494fb93cebbfad028d9b0e
https://doi.org/10.1182/blood.v118.21.5135.5135
https://doi.org/10.1182/blood.v118.21.5135.5135